HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA, EPA Sharing Data; Industry Lead-In-Cosmetics Petition Goes Unanswered; More

This article was originally published in The Rose Sheet

Executive Summary

FDA could use data collected under the Toxic Substances Control Act to inform its risk-assessment work, a March 16 update indicates, announcing a memorandum of understanding between FDA and the Environmental Protection Agency. More news in brief.

You may also be interested in...



EWG Lawsuit Slams FDA’s Failure To Act On ‘Formaldehyde-Laced’ Hair Smoothers

The Environmental Working Group seeks decisive FDA action on formaldehyde in heated hair-smoothing products, as requested in its 2011 citizen petition, with a complaint filed in District of Columbia District Court. The suit doubles as a reminder to Congress and consumers that cosmetics regulations are overdue for an update, the NGO says.

FDA Warns Public About Products Posing Heavy-Metal Exposure Risks

FDA lab analysis of Alikay Naturals' Bentonite Me Baby identified elevated lead levels posing potential risks to consumers, the agency says in a Jan. 28 safety alert, while the company suggests FDA has mischaracterized its product and intended use. A same-day consumer warning cites hazardous mercury content in a skin cream largely available in Spanish-speaking communities.

Congress Proposes Public-Private Partnership For CIR

In reports accompanying draft fiscal 2016 funding bills, both House and Senate committees recommend that FDA work with industry to explore formalizing the Cosmetic Ingredient Review via a public-private partnership similar to that in place with the U.S. Pharmacopeial Convention.

Related Content

Related Companies

UsernamePublicRestriction

Register

RS019436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel